References
- Blumberg H., Pachter I.J., Matossian Z., U.S.Patent 3,332,950, July 25, 1967
- Blumberg H., Dayton H. B. Naloxone and related compounds Agonist and Antagonist Actions of Narcotic Analgesic Drugs. Proceedings of a British Pharmacological Society Symposium. 1971, H. W. Kosterlitz, H.O.J. Collier, J. E. Villarreal. Macmillan, Aberdeen, Scotland, New York July, 1973
- Kosterlitz H. W., Watt A. J. “Kinetic parameters of narcotic agonists and antagonists,”. Reported to the Committee on Problems of Drug Dependence and published in the proceeding of the 30th meeting held in Indianapolis, Indianapolis, 1968. Indiana
- Villarreal J. E., Seevers M. H. (1970) “Evaluation of new compounds for morphinelike physical dependence in the rhesus monkey,”. Reported to the Committee on Problems of Drug Dependence and published in the proceedings of the 32nd meeting. 1970. Washington, DC, addendum 1
- Martin W. R., Jasinski D. R. Characterization of N-cyclopropylmethyl-7,8-dihydro-14-hydroxynormorphine HC1 a narcotic antagonist. Clin. Pharmacol. Ther. 1973; 14: 142
- Blumberg H., Dayton H. B. Naloxone, naltrexone, and related noroxy-morphines. Narcotic Antagonists, M. C. Braude, L. S. Harris, E. L. May, J. P. Smith, J. E. Villarreal. Raven, New York 1974, (Advances in Biochemical Psychopharmacology Vol. 8)
- Gray A. P., Robinson D. S. Naltrexone zinc tannate: A prolonged-action narcotic antagonist complex. J Pharm. Sci. 1974; 63: 159–161
- Martin W. R., Jasinski D. R., Mansky P. A. Naltrexone an antagonist for the treatment of heroin dependence. Arch. Gen. Psychiatry 1973; 28: 784–791
- Resnick R., Volavka J. Reported to the Committee on Problems of Drug Dependence and published in the proceedings of the 36th meeting held in Mexico City, Mexico City, 1974. Mexico
- Resnick R. B., Volavka J., Freedman A. M., Thomas M. Studies on EN-1638A (naltrexone): A new narcotic antagonist. Am. J. Psychiatry 1974; 131: 6
- Cone E. J. Human metabolite of naltrexone (N-cyclopropylmethylnoroxy-morphone) with a novel C-6 isomorphine configuration. Tetrahedron Lett. 1973; 23: 2607–2610
- Chatterjie N., Fujimoto J. M., Inturrisi C. E., Roerig S., Wang R. I. H., Bowen D. V., Field F. H., Clarke D. D. Isolation and stereochemical identification of a metabolite of naltrexone from human urine. Drug Metab. Disposition 1974; 2: 401–405
- Cone E. J., Gorodetzky C. W., Yeh S. Y. Biosynthesis, isolation, and identification of β-hydroxynaltrexone. Pharmacologist 1974; 16: 225
- Pollock S. H., Fujimoto J. M. A partial characterization of naloxone and naltrexone-6-ketone reductase in rabbit and chicken. Pharmacologist 1974; 16: 225
- Fujimoto J. M., Roerig S., Wang R. I. H., Chatterjie N., Inturrisi C. E. Proc. Soc. Exp. Biol. Med. 1975; 148: 443–448
- Cone E. J., Gorodetsky C. W., Yeh S. Y. The urinary excretion profile of naltrexone and metabolites in man. Drug Metab. Disposition 1974; 2: 506–512
- Verebey K., Mule S. J., Jukofsky D. Quantitation of naltrexone in human urine using gas-liquid chromatography. Pharmacologist 1974; 16: 225
- Verebey K., Mulé S. J., Jukofsky D., Unpublished Observations
- Inturrisi C. E., Personal Communications